GlassScriptPhysician profile
Henry Matthews Ramirez
NPI 1275589632
$951.03
in general payments reported to CMS, 2019-2025
28 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $659 · 2022: $42.32 · 2023: $36.98 · 2024: $79.36 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $249.35 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $134.28 | 2021-2024 | Jardiance |
| Abbott Laboratories | $57.53 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.79 | 2021 | |
| Abbvie INC. | $39.15 | 2021 | |
| Pfizer INC. | $36.78 | 2021 | |
| Boston Scientific Corporation | $35.90 | 2025 | Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.54 | 2023-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $26.03 | 2021 | |
| Dexcom, INC. | $24.64 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $21.26 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.86 | 2023 | Rexulti |
| Lundbeck LLC | $19.08 | 2021 | |
| Esperion Therapeutics, INC. | $18.10 | 2021 | |
| Corcept Therapeutics | $17.62 | 2025 | Korlym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $16.98 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $16.89 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $16.16 | 2021 | |
| Adlon Therapeutics L.P. | $14.46 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.90 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.55 | 2021 | |
| Glaxosmithkline, LLC. | $12.91 | 2021 | |
| Merck Sharp & Dohme LLC | $12.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.07 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.13 | 2021 | |
| Eisai INC. | $11.12 | 2021 | |
| Forte Bio-Pharma LLC | $10.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.